Abstract:Abstract BackgroundGrowing evidence has indicated that dysregulation of ferroptosis is associated with atherosclerosis. Dapagliflozin as a sodium glucose cotransporter 2 inhibitor (SGLT2i), in view of the clinically important benefits in improving cardiovascular outcomes, we aimed to explore its pharmacological effects and underlying mechanisms of atherosclerosis associated with ferroptosis.MethodFerroptosis and severity of atherosclerosis were assessed in ApoE-/- (control) and ApoE-/-+ Dapagliflozin (SGLT2i) mice groups to analyze the changes after Dapagliflozin treatment. ApoE-/-+Dapagliflozin+RSL3 (RSL3) mice group was established to confirm the association between ferroptosis and severity of atherosclerosis. Metabolism of macrophages sorted by FACS within atherosclerosis plaques were analyzed to explore the mechanism of Dapagliflozin attenuating the severity of atherosclerosis.ResultAlleviated severity of atherosclerosis and ferroptosis were observed in Dapagliflozin treatment mice group, however, RSL3 treatment mice group revoke the beneficial effect. The metabolism of macrophages sorted by Fluorescence activated Cell Sorter (FACS) within atherosclerosis plaques from Dapagliflozin treatment mice group indicated an energy crisis which mitigates ferroptosis and keeps more M2 macrophages surviving in atherosclerotic plaques.ConclusionDapagliflozin treatment attenuates severity of atherosclerosis by the way of creating energy crisis to keep more M2 macrophages surviving in atherosclerotic plaque which is more sensitive to ferroptosis than M1.

Dapagliflozin attenuates severity of atherosclerosis through manufacturing energy-crisis to inhibit ferroptosis of macrophage